COVID-19 and Phytotherapy

被引:4
|
作者
Akbas, Melike Nur [1 ]
Akcakaya, Adem [2 ]
机构
[1] Bezmialem Vakif Univ, Phytopharm, Istanbul, Turkey
[2] Bezmialem Vakif Univ, Fac Med, Dept Gen Surg, Istanbul, Turkey
来源
BEZMIALEM SCIENCE | 2020年 / 8卷 / 04期
关键词
COVID-19; coronavirus; phytotherapy; comlementary therapy; RESPIRATORY-TRACT INFECTIONS; DOUBLE-BLIND; SAMBUCUS-NIGRA; ELDERBERRY; EXPRESSION; LICORICE; CURCUMIN; INJURY;
D O I
10.14235/bas.galenos.2020.4962
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2), emerging in Wuhan city, China, causing COVID-19 disease, has been described as a pandemic by WHO (World Health Organization), leading to outbreaks of pneumonia. The COVID-19 pandemic continues to affect millions of people worldwide. SARS-COV-2 enters the cell via ACE-2 (Angiotensin-converting enzyme 2) receptor. These receptors are predominantly found in lung, small intestine, and vascular endothelial cells. Since ACE 2 is found more frequently in these tissues, common clinical symptoms include fever, cough, sore throat, fatigue, dyspnea, and diarrhea. Currently, although symptomatic treatments are applied for COVID-19, there is no specific treatment yet. It takes a long time before targeted therapies can be found. For this reason, it is necessary to develop emergency treatment or methods that can quickly control the disease. Phytotherapeutic compositions offer a potentially valuable resource for this purpose. Many countries, especially China, aimed to reduce morbidity and mortality by using phytotherapy throughout COVID-19 patients. Phytotherapeutic products are known to be safe and tolerable with their background knowledge. In this regard, the use of phytotherapy as a complementary treatment in COVID-19 patients is very important. In this review, phytotherapeutic approaches related to symptoms that may occur in the clinical course of COVID-19 disease will be discussed.
引用
收藏
页码:428 / 437
页数:10
相关论文
共 50 条
  • [41] Of chloroquine and COVID-19
    Touret, Franck
    de lamballerie, Xavier
    ANTIVIRAL RESEARCH, 2020, 177
  • [42] Eosinopenia and COVID-19
    Tanni, Fahmina
    Akker, Eleonora
    Zaman, Muhammad M.
    Figueroa, Nilka
    Tharian, Biju
    Hupart, Kenneth H.
    JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, 2020, 120 (08): : 504 - 508
  • [43] Epidemiology of COVID-19
    Dhar Chowdhury, Sudipta
    Oommen, Anu Mary
    JOURNAL OF DIGESTIVE ENDOSCOPY, 2020, 11 (01) : 3 - 7
  • [44] Pathogenesis of COVID-19
    Akpinar, Evrim Eylem
    EURASIAN JOURNAL OF PULMONOLOGY, 2020, 22 (04) : 8 - 11
  • [45] COVID-19 and HIV
    Paulina Posada-Vergara, Maria
    Carlos Alzate-Angel, Juan
    Martinez-Buitrago, Ernesto
    COLOMBIA MEDICA, 2020, 51 (02):
  • [46] Psychopharmacology of COVID-19
    Bilbul, Melanie
    Paparone, Patricia
    Kim, Anna M.
    Mutalik, Shruti
    Ernst, Carrie L.
    PSYCHOSOMATICS, 2020, 61 (05) : 411 - 427
  • [47] Pathophysiology of COVID-19
    Manta, Bruno
    Sarkisian, Armen G.
    Garcia-Fontana, Barbara
    Pereira-Prado, Vanesa
    ODONTOESTOMATOLOGIA, 2022, 24 (39):
  • [48] COVID-19 in Pediatrics
    Case, Siobhan Mary
    Son, Mary Beth
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2021, 47 (04) : 797 - 811
  • [49] Misinformation and COVID-19
    Hussaini, Najia
    Varon, Joseph
    CURRENT RESPIRATORY MEDICINE REVIEWS, 2021, 17 (02) : 59 - 59
  • [50] COVID-19 and the pituitary
    Frara, Stefano
    Allora, Agnese
    Castellino, Laura
    di Filippo, Luigi
    Loli, Paola
    Giustina, Andrea
    PITUITARY, 2021, 24 (03) : 465 - 481